Method of diagnosing or prognosing psoriatic arthritis
AssigneeUniversity College Dublin
InventorsStephen Pennington, Oliver Fitzgerald, Angela Mc Ardle
Life of this patent
Estimating the term…
Abstract
The present invention relates to methods of diagnosing or prognosing arthritis, specifically methods of diagnosing or prognosing psoriatic arthritis. Also disclosed are methods of diagnosing or prognosing rheumatoid arthritis, and methods of differentiating psoriatic arthritis from rheumatoid arthritis. Specifically, the methods involve determining the quantitative or qualitative level of one or more biomarkers in a biological sample from a subject.
Claims14
A method of treating psoriatic arthritis in a subject, the method comprising:
- (a) determining the quantitative or qualitative level of two or more peptides in a blood sample from a subject, the two or more peptides comprising a peptide of Rheumatoid factor C6 light chain having an amino acid sequence ASSLESGVPSR (SEQ ID NO:1) and a peptide of Leucine-rich alpha-2-glycoprotein having an amino acid sequence VAAGAFQGLR (SEQ ID NO:
- 2);
- and
- (b) differentiating psoriatic arthritis from rheumatoid arthritis in the subject, wherein the quantitative or qualitative level of Rheumatoid factor C6 light chain is increased in rheumatoid arthritis, and treating the subject with a therapy for psoriatic arthritis selected from the group consisting of methotrexate, an anti-TNFα inhibitor, ustekinumab, apremilast, and an anti-IHL17 therapy.
A method of treating psoriatic arthritis in a subject, the method comprising:
- (a) determining the quantitative or qualitative level in a blood sample from a subject of Rheumatoid factor C6 light chain peptide having an amino acid sequence of SEQ ID NO:1 and Leucine-rich alpha-2-glycoprotein peptide having an amino acid sequence of SEQ ID NO:2, wherein the level is measured by performing mass spectrometry comprising multiple reaction monitoring (MRM);
- and
- (b) differentiating psoriatic arthritis from rheumatoid arthritis in the subject, wherein the quantitative or qualitative level of Rheumatoid factor C6 light chain is increased in rheumatoid arthritis, and treating the subject with a therapy for psoriatic arthritis selected from the group consisting of methotrexate, an anti-TNFα inhibitor, ustekinumab, apremilast, and an anti-IHL17 therapy.
Dependencies are inferred from the claim text.